**Vault RNA1-1 riboregulates the autophagic function of p62 by binding to K7/R21
that are critical for p62 oligomerisation**

Magdalena Büscher^{1,2}, Rastislav Horos^{1,3}, Ina Huppertz^{1,3}, Kevin Haubrich¹, Nikolay Dobrev¹, Florence Baudin¹, Janosch Hennig¹, Matthias W. Hentze^{1,*}

¹European Molecular Biology Laboratory, 69117 Heidelberg, Germany

²Collaboration for joint PhD degree between EMBL and Heidelberg University, Faculty of Biosciences, Heidelberg, Germany

³Equal contribution

*To whom correspondence should be addressed: hentze@embl.org

Running Title: Mechanism of p62 riboregulation by vtRNA1-1

Keywords: riboregulation, vault RNA, p62, autophagy, small ncRNA

29 ABSTRACT

30

31 Cellular processes can be regulated at multiple levels, including transcriptional, post-
32 transcriptional and post-translational mechanisms. We have recently shown that the
33 small, non-coding vault RNA1-1 negatively riboregulates p62 oligomerisation in
34 selective autophagy through direct interaction with the autophagic receptor. This
35 function is highly specific for this Pol III transcript, but the determinants of this
36 specificity and a mechanistic explanation of how vault RNA1-1 inhibits p62
37 oligomerisation are lacking. Here, we combine biochemical and functional
38 experiments to answer these questions. We show that the PB1 domain and adjacent
39 linker region of p62 (aa 1-122) are necessary and sufficient for specific vault RNA1-1
40 binding, and identify lysine 7 and arginine 21 as key hinges for p62 riboregulation.
41 Chemical structure probing of vault RNA1-1 further reveals a central flexible loop
42 within vault RNA1-1 that is required for the specific interaction with p62. Overall, our
43 data provide molecular insight into how a small RNA riboregulates protein-protein
44 interactions critical to the activation of specific autophagy.

INTRODUCTION

Macroautophagy ensures the clearance of intracellular substrates ranging from single ubiquitinated proteins to large proteotoxic aggregates and defective organelles. The human autophagy receptor p62 (also known as SQSTM1, ZIP or ORCA) guides selective macroautophagy of intracellular cargo to maintain homeostasis in situations of proteotoxic stress or starvation (Bjørkøy et al. 2005; Dikic 2017; Lim et al. 2015). Following activation, p62 oligomerizes and forms large protein assemblies – so-called sequestosomes – that guide intracellular cargo to the elongating autophagic membrane (Jakobi et al. 2020). Upon complete enclosure of the assemblies, the autophagosome fuses with lysosomes to degrade its content and recycle the building blocks for further cellular utilization.

In this process, p62 recognises ubiquitinated cargo via its C-terminal ubiquitin-associated (UBA) domain (Zaffagnini et al. 2018) and N-arginylated proteins via its ZZ-type zinc finger domain, respectively (Cha-Molstad et al. 2017). The central LC3-interacting region (LIR) binds the ATG8-like proteins LC3 and GABARAP, thereby bridging intracellular cargo to the autophagic membrane (Pankiv et al. 2007).

Since the affinity of p62 monomers for specific cargo and the ATG8-like proteins is rather modest, protein oligomerisation is essential to achieve high avidity protein interactions while maintaining selectivity (Wurzer et al. 2015). Oligomerisation is mediated by the N-terminal Phox and Bem1 (PB1) type I/II domain that comprises an OPCA motif (short for OPR: octicosapeptide repeat, PC: Phox and Cdc motif, AID: Atypical protein kinase C interaction domain) and a conserved lysine which can align in a head to tail-fashion (Ciuffa et al. 2015; Ito et al. 2001; Lamark et al. 2003). Strikingly, mutations that disrupt PB1 domain-mediated oligomerisation prevent p62 engagement in autophagy and thereby highlight the ‘effector’ function of PB1-

71 mediated oligomerisation in this process (Bjørkøy et al. 2005; Itakura and Mizushima
72 2011; Jakobi et al. 2020; Lamark et al. 2003; Sun et al. 2018). Intrinsic modulators of
73 p62 oligomerisation include the formation of stabilising disulphide bonds between
74 cysteine 105 and 113 upon oxidative stress or ZZ domain binding (Carroll et al. 2018;
75 Cha-Molstad et al. 2017), as well as inhibitory posttranslational modifications within
76 the oligomerisation interface (Christian et al. 2014; Pan et al. 2016). Besides, the linker
77 region between the PB1- and ZZ domain of p62 (aa 100-113) was shown to auto-
78 regulate p62 by interaction with the ZZ domain (Zhang et al. 2018).

79 We recently discovered that the small non-coding vault RNA1-1 directly binds
80 to p62 and regulates p62 oligomerisation and hence function in autophagy (Büscher
81 et al. 2020; Horos et al. 2019). Vault RNAs are transcribed by RNA polymerase III and
82 were originally identified more than three decades ago as components of the so-called
83 vault particle (Kedersha and Rome 1986). The four human vault RNA paralogs share
84 almost identical sequences at their 3' and 5' ends while their central domains vary in
85 sequence and length (Supplementary figure 3; Nandy et al. 2009; Stadler et al. 2009).
86 We found that vault RNA1-1 is a prime p62-interacting vault RNA, but the molecular
87 determinants of their specific interaction and the mechanism of how these control
88 oligomerisation remained unresolved (Horos et al. 2019). We previously described a
89 ZZ domain mutant (R139A/K141A) and a PB1 domain mutant (R21A/D69A/D73A) that
90 both exhibit reduced RNA binding while showing increased or diminished
91 oligomerization, respectively (Horos et al. 2019). These findings implicated a role for
92 both domains in riboregulation, suggesting that either the PB1 domain itself or PB1
93 domain-mediated oligomerization may be required for p62's RNA binding activity
94 (Horos et al. 2019). Here, we delineate key determinants of p62 and vault RNA1-1 that
95 mediate binding and specificity of the p62 - vault RNA1-1 interaction. We uncover the
96 specific importance of two the amino acids lysine 7 and arginine 21 in riboregulation

97 and suggest their function as hinges between oligomerization and RNA binding. We
98 also identify the central loop of vault RNA1-1 as a specific determinant of p62 binding
99 compared to the other human vault RNAs. Thereby our results elucidate critical
100 molecular details of this prime example of riboregulation.

101

RESULTS

The PB1 oligomerisation domain and adjacent linker region of p62 mediate specific vault RNA1-1 binding

To identify the region of p62 that is required for RNA binding in a systematic manner, we generated a series of FLAG-HA tagged p62 truncation constructs (Figure 1A), and assessed their RNA-binding capacity via polynucleotide kinase (PNK) assay in p62 knockout (KO) HuH-7 cells (Figure 1B). In this assay, UV-crosslinking introduces covalent bonds between p62 and bound RNAs. Subsequently the cells are lysed, and lysates subjected to limited RNase treatment before p62 immunoprecipitation and end-labelling of crosslinked RNA with PNK (Figure 1B). The eluates are resolved by SDS-PAGE and total RNA binding is assessed by phosphorimaging and Western blotting, respectively. Although UV-crosslinking is not considered to promote protein-protein crosslinking in general (Greenberg 1979; Pashev et al. 1991; Suchanek et al. 2005), we noticed earlier that p62 oligomers can be UV-crosslinked, allowing the assessment of the oligomerization status of p62 in addition to RNA binding (Horos et al. 2019).

We find that the N-terminal 172 amino acids of p62 carry the full RNA-binding capacity compared to the full-length (FL) protein (Figure 1C and D). Additional deletion of the ZZ domain, leaving only the PB1 domain and adjacent C-terminal linker region of p62 (p62₁₋₁₂₂; aa 1-122) significantly increases normalised RNA binding above the level of wild type p62, suggesting a negative modulatory function of the ZZ domain on RNA binding. However, the PB1 domain alone (aa 1-102) or the ZZ domain with the linker (aa 102-172) display little if any RNA-binding capacity (Figure 1C and D). These data

map the relevant RNA-binding interfaces to p62₁₋₁₂₂. By contrast, the ZZ domain (aa 115-172) may play a regulatory role (Figure 1C and D; see below).

To specifically assess vault RNA 1-1 binding under steady-state (i.e. non-crosslinking) conditions, we performed native immunoprecipitation followed by RT-qPCR of co-purified RNA (RIP). In this assay, p62₁₋₁₂₂ displays specific and maximal vault RNA1-1 binding compared to full-length p62 (Figure 1E, Supplementary Figure 1). In contrast, p62 association with the other vault RNA paralogs is not significantly changed. These findings reflect the prime role of vault RNA1-1 in p62 riboregulation as previously observed (Horos et al., 2019) and hint towards differences between the vault RNA paralogues that mediate differential binding.

We conclude that p62₁₋₁₂₂ - the PB1 oligomerisation domain with its adjacent C-terminal linker - accounts for specific vault RNA1-1 binding to p62. This result is unexpected in the light of the previously identified ZZ domain mutant R139A/K141A, which showed reduced RNA binding and implicated the ZZ domain as a critical region for the RNA interaction (Horos et al. 2019). The data presented here shed new light on this mutant and suggest a regulatory role for the ZZ domain in RNA binding.

Hinge residues K7 and R21 are necessary for both, RNA binding and p62 oligomerisation

We next generated FLAG-HA tagged mutant constructs of p62 to i) assess, whether RNA binding depends on oligomerisation, and ii) to narrow down the RNA-binding interface in the context of full-length p62. To prohibit PB1-dependent oligomerisation, we mutated the negatively charged OPCA motif (Figure 2A) introducing single (D69A), double (D69A/D71A) or triple amino acid (D69A/D71A/D73A) exchanges (Lamark et al. 2003). We assessed multimerization of the different constructs *in cellulo* by measuring the ratio of p62 complexes with slower

153 migration in SDS-PAGE over the total p62 amounts in PNK assays. As expected, all
154 mutants display decreased oligomerization compared to the wild-type control and to
155 each other with increasing mutations (Figure 2B, Supplementary Figure 2B). Yet, their
156 RNA-binding capacity is not significantly changed (Figure 2B, Supplementary Figure
157 2). In addition to the *in cellulo* experiments, we used maltose-binding protein (MBP)-
158 tagging to generate recombinant p62 with low oligomerization potential (Horos et al.
159 2019; Reuten et al. 2016; Tarafder et al. 2019) and tested *in vitro* binding of vault
160 RNA1-1. This analysis confirms that the RNA-binding affinity of p62 is not affected by
161 a double mutation of residues D69 and D73 (Supplementary Figure 2A).

162 Next, we performed ^1H , ^{15}N -HSQC NMR spectroscopy with the minimal
163 construct p62₁₋₁₂₂ which we forced into a monomeric form by the before-characterised
164 triple mutation (D69A/D71A/D73A). We recorded spectra with and without equimolar
165 amounts of *in vitro* transcribed full-length vault RNA1-1 to assess binding (Figure 2C).
166 The spectra revealed strong signal loss for most peaks and multiple chemical shift
167 perturbations for the remaining peaks upon addition of the RNA, indicating complex
168 formation. Together, these findings show that the PB1 domain and adjacent C-terminal
169 linker region of p62 are sufficient for direct and specific vault RNA1-1 binding and that
170 oligomerisation is not required for this interaction.

171 To pinpoint the RNA-binding interface of p62, we mutated positively charged
172 amino acids within the PB1 domain (Figure 2A) and adjacent linker region. This
173 strategy yielded three classes of mutants (Figure 2D and E). First, PB1 domain
174 mutants with decreased RNA binding and impaired oligomerization - namely p62 K7A
175 and K21A. Second, those that display decreased RNA binding without significant
176 changes in oligomerization, including R22A and R96A. And finally, the linker mutants
177 K102A/K103A, R106A/R107A and H109A/R110A that show reduced RNA binding and

178 increased multimerization. This latter group also includes the previously identified p62
179 ZZ domain mutant R139A/K141A (Horos et al. 2019), which we included for reference.

180 Previous mutational studies showed that residues K7 and R21 are necessary
181 for p62 multimerization, while R22 is not (Lamark et al. 2003). The PNK assay reflects
182 this finding, confirming its utility as a tool to monitor p62 multimerization. Our data
183 highlight residues K7 and R21 as critical residues for RNA binding and hence
184 riboregulation, suggesting that RNA binding directly interferes with multimerization.

185 By contrast, R22 and R96 appear to extend the RNA-binding interface without
186 making a strong contribution to multimerization in the absence of RNA binding.
187 Mutations in the linker region or ZZ domain of p62 both resulted in reduced RNA
188 binding and increased presence of multimers (Figure 2D and E). To distinguish
189 whether in these cases the loss of RNA binding resulted in multimerization or
190 conversely multimer formation displaced the RNA, we performed EMSAs with
191 recombinant p62 that we forced into a low-oligomeric form by MBP-tagging (Horos et
192 al. 2019; Reuten et al. 2016; Tarafder et al. 2019). We observed decreased vault
193 RNA1-1 association for recombinant MBP-p62 K7A and R21A (Figure 2F,
194 Supplementary Figure 2C and D), confirming the direct involvement of these residues
195 in RNA binding. In contrast, the RNA-binding capacity of the linker mutant MBP-p62
196 R106A/R107A (Figure 2F) or the ZZ domain mutant MBP-p62 R139A/K141A was not
197 impaired (Supplementary Figure 2E). These results favour the interpretation that
198 mutations targeting the linker and ZZ domain foster multimeric forms of p62 *in cellulo*
199 that exclude RNA from binding to the autophagic receptor.

Vault RNA 1-1 forms a central flexible loop that mediates binding and specificity of the p62 interaction

The tertiary structure of vault RNA1-1 is presently unknown. Previous secondary structure analyses using RNase H probing were useful but limited in resolution (Nandy et al. 2009; Poderycki et al. 2005). We applied chemical structure probing in solution to identify relevant features of vault RNA1-1 at nucleotide resolution (Figure 3A and C, circles). The low reactivity of the conserved ends of vault RNA1-1 towards the probing reagents and their high base complementarity suggest that the ends of vault RNA1-1 form a base-paired stem. This interpretation fits well with previous thermodynamic models and is furthermore supported by the inter-species conservation of their base-pairing potential. In contrast, the central part of vault RNA1-1 forms a highly reactive flexible loop region that was previously not anticipated (Figure A and 3C, circles). This finding is further supported by orthogonal transcriptome-wide RNA secondary structure probing data that are publicly available (Supplementary Figure 4 (Li et al. 2021; Sun et al. 2019)).

Next, we conducted RNase A footprinting to identify vault RNA1-1 residues that are protected by p62 binding (Figure 3B and C, grey arrows). Several protected regions emerge in the presence of p62. These include single-stranded bulges within the stem and, prominently, the central flexible loop. Of note, the protected nucleotides in the central loop completely match the crosslinked nucleotides previously identified by iCLIP of p62 (Figure 3C, dots (Horos et al. 2019)). When compared with the other three human vault RNA paralogs, the central loop of vault RNA1-1 differs considerably in length and sequence (Supplementary Figure 3). Overall, our data implicate nucleotides within the central loop of vault RNA 1-1 as specific p62 contact points.

Nucleotides within the central flexible loop of vault RNA1-1 determine p62 riboregulation *in cellulo*

To validate the functional importance of the central flexible loop region of vault RNA 1-1 for riboregulation of p62, we generated a HuH-7 Flp-IN vault RNA1-1 KO cell line with a single FRT integration site. This KO cell line thus allowed the stable and isogenic re-integration of vault RNA1-1 variants expressed from the endogenous promoter (Supplementary Figure 5). We compared re-integrated wild-type vault RNA1-1 with two mutants that alter either the central loop triplet U36/U37/U38 alone (M1) or in combination with residues A46/C47 (M2; Figure 4A). The expression levels of all three re-integrated vault RNA1-1 variants are similar to each other and correspond to approximately 50% of the vault RNA1-1 levels in the parental wild type HuH-7 Flp-IN cell line (Figure 4B and C). This expression level is in line with the single FRT integration site and, also reflected in a reduced vault RNA1-1 association with p62 as measured by native IP of p62 followed by RT-qPCR quantification (Figure 4D, Supplementary figure 5E). As expected, the central domain mutants M1 and M2 tend to show reduced p62 binding *in cellulo* compared to the wild-type vault RNA1-1 (Figure 4D, Supplementary figure 5E). This conclusion is further supported *in vitro* by EMSAs, where the mutations in the central loop of vault RNA1-1 compete less well for p62 binding than the wt counterpart (Supplementary Figure 6A). This assay also shows that the central loop region of vtRNA1-1 alone is not sufficient for p62 binding *in vitro* (Supplementary Figure 6A) and reveals the importance of the 3D structure of vtRNA1-1 for p62 binding.

Finally, we tested how the loop mutations affect p62 riboregulation *in cellulo*. As established before [19], we stimulated autophagy in the reconstituted cells with the synthetic, p62-specific ZZ-domain ligand XIE62-1004-A (Cha-Molstad et al. 2017) and assessed the LC3II/LC3I ratio as a measure of autophagic flux by Western blotting.

Consistent with our earlier data, the autophagic flux is significantly greater in cells depleted of vault RNA1-1 compared to the respective CRISPR/Cas9 control cell line upon treatment, as evidenced by the increased ratio of LC3BII/LC3BI (Figure 4E and F). Re-integration of wild-type vault RNA1-1 rescues this phenotype significantly, whereas the central loop mutants fail to do so (Figure 4E and F). Thus, residues within the central loop of vault RNA1-1 are required for the efficient riboregulation of p62-mediated autophagy *in cellulo*.

DISCUSSION

Earlier work unveiled riboregulation as a new modality of posttranslational protein regulation: to limit autophagic flux, p62 oligomerization is inhibited by direct vtRNA1-1 binding (Büscher et al. 2020; Horos et al. 2019). This discovery raised the key questions of how vtRNA1-1 interferes with oligomerization and how specificity is achieved compared to the other three human vault RNA orthologs and other tRNA-like Pol III transcripts. The work presented here addresses these mechanistic questions and uncovers critical features that determine binding and specificity of the p62-vtRNA1-1 riboregulatory pair. It reveals molecular details of how vtRNA1-1 modulates p62 function by interference with PB1 domain-mediated oligomerisation. This work therefore explores an unprecedented function of non-coding RNA as posttranslational protein regulators and defines critical mechanistic details of how vtRNA1-1 inhibits p62 oligomerisation.

In detail, we show that the PB1 domain and adjacent linker region (p62₁₋₁₂₂) are both necessary and sufficient for maximal specific vtRNA1-1 binding. Mutational analyses pinpoint to K7 and R21 as critical amino acids that are necessary for RNA binding (Figure 2) in addition to their previously known role in p62 oligomerisation

(Lamark et al. 2003). This result identifies these two residues as hinges for riboregulation, through which vtRNA1-1 inhibits p62 oligomerisation and consequently autophagy.

Our initial report identified two mutants in the ZZ domain (K141A and R139A/K141A) that showed strongly diminished RNA binding and increased p62 oligomerization ([19]; see also Figure 2D and E). Interestingly, the three new linker domain mutants K102A/K103A, R106A/R107A and H109A/R110A display the same phenotype (Figure 2E and F). Importantly, the ZZ domain had previously been shown to bind arginylated substrates (N-degrons) (Cha-Molstad et al. 2017; Zhang et al. 2018), a process that triggers p62 oligomerisation and thereby initiates autophagic clearance. In this context, the linker region (p62₁₀₀₋₁₁₃) was shown to exert negative autoregulation through direct interaction with the ZZ domain (Zhang et al. 2018). In the light of our new data (Figure 2), we hypothesize that the above mutations within the linker region or the ZZ domain, respectively, render this autoinhibitory mechanism dysfunctional, resulting in constitutive activation of the clearance pathway and increased p62 oligomerization. Of note, the auto-regulatory linker overlaps exactly with all PB1 domain mutants that show a significant increase in multimerization. In further support of this model, R139 has been shown to directly interact with the inhibitory linker and stabilise the autoregulatory interaction (Zhang et al. 2018). The exclusion of RNA from p62 oligomers that are formed upon activation of ZZ domain-mediated autophagic clearance would ensure efficient aggregate clearance even in situations when cellular levels of the vault RNA1-1 riboregulator are high, including for example some viral infections (Amort et al. 2015; Li et al. 2015; Mrázek et al. 2007; Nandy et al. 2009).

As proposed before, our new data further corroborate that vault RNA1-1 primarily inhibits p62 oligomerisation. Our new data also suggest that vtRNA1-1 may

not be able to disrupt p62 oligomers that are formed when cargo binds to the ZZ domain. Integrating all available experimental evidence, we now suggest a refined mechanistic model for riboregulation of p62 by vtRNA1-1: under physiological, nutrient-replete conditions, vtRNA1-1 inhibits p62 oligomerisation by binding the critical hinge points K7 and R21. When starvation reduces cellular vtRNA1-1 levels, p62 oligomerisation via K7 and R21 is facilitated, stimulating autophagic flux (Supplementary Figure 6B; [19]). By contrast, cargo binding to the ZZ domain and linker region during proteotoxic stress (Cha-Molstad et al. 2018; Zhang et al. 2018) triggers 'sequestosome' formation and cargo clearance even when vtRNA1-1 levels are high, excluding vtRNA1-1 sterically in a dominant fashion (Supplementary Figure 6B).

To also decipher the riboregulatory interface(s) of vtRNA1-1, we identified nucleotides required for p62 binding (Figure 3-4). We identify nucleotides within a central loop region of vtRNA1-1 that are necessary for the interaction and for specific riboregulation of p62 function in autophagy. However, further nucleotides likely contribute to an extended binding interface. Interestingly, this region of vtRNA1-1, especially nucleotides 45-50, had previously been shown to mediate apoptosis resistance in Hela cells (Amort et al. 2015; Bracher et al. 2020). While the molecular details of this phenotype remain unclear, our findings suggest the modulation of autophagy-dependent apoptosis via p62 as a possibility deserving of further exploration.

The p62-vtRNA1-1 binding interface may well be targeted by regulatory modifications that potentially influence riboregulation. For example, K7 has previously been found to be ubiquitinated by TRIM21 (Pan et al. 2016). Like vtRNA1-1 binding, this ubiquitination prevents p62 oligomerisation and also facilitates proteasomal degradation of p62. By contrast, vtRNA1-1 riboregulation may represent a more

dynamic and reversible form of autophagy inhibition that preserves p62 integrity. It will be interesting to systematically examine other protein or RNA modifications that could play a role for riboregulation.

Our data also demonstrate that autophagic clearance can be modulated by experimental changes of intracellular vault RNA1-1 levels (Figure 4). Modulation of riboregulation could be especially beneficial in instances, where the cargo load exceeds the capacity of cellular degradation mechanisms, as it is the case in neurodegenerative diseases or cancer (Nixon 2013; Yang and Klionsky 2020).

In addition to its function as an autophagy receptor, p62 provides a platform for key cellular signalling pathways (Duran et al. 2011; Katsuragi et al. 2015; Lee et al. 2010; Moscat et al. 2016). While we have not detected changes in mTOR signalling upon depletion of vtRNA1-1 in HuH-7 cells (Horos et al. 2019), it will be interesting to explore globally whether RNA1-1 depletion or the expression of RNA-binding deficient p62 mutants affect other cellular signalling pathways.

With hundreds of newly identified RNA-binding proteins (Gebauer et al. 2020), riboregulation may represent a more widespread mechanism for the regulation of other key cellular processes beyond autophagy. From this perspective, the vtRNA1-1/p62 interaction offers a paradigm for the interference of a riboregulatory RNA with protein-protein interactions.

Limitations of this study

This work provides a structure-function analysis to identify critical residues of p62 and vtRNA1-1, respectively, for the specific interaction between the two partners and their function in the riboregulation of p62 in mammalian autophagy. As such, it answers what distinguishes vtRNA1-1 from the other three human vtRNAs, and how vtRNA1-1 achieves control of p62 oligomerization via K7 and R21. In the future, it will be

important to examine this interaction at atomic resolution using state of the art structural technologies.

Since our experiments have been conducted with cultured human cells, it will also be interesting to examine *in vivo* models (e.g. mice) expressing the mutant RNAs and forms of p62, respectively, which we have defined in this work. The investigation of animal models and clinical samples in the context of viral infections, cancer or neurodegenerative disorders will advance our understanding of the functional importance of p62 riboregulation in organismal function and disease.

MATERIAL AND METHODS

Antibodies and reagents. Antibodies and reagents used in this study are listed in Supplementary Table 1.

Cell lines and culture conditions. HuH-7 cells (derived from a hepatocellular carcinoma of a human aged 57 years) and their derivatives were cultured in DMEM containing 1 g/l glucose supplemented with 10% heat-inactivated FCS (Fetal Calf Serum, Gibco, Cat#: 10270-106), 2 mM L-glutamine (Thermo Scientific, Cat#: 25030081) and 100 U/ml Penicillin/Streptavidin (Thermo Scientific, Cat#: 15140122) at 37°C and 5% CO₂. The cells were routinely passaged 2-3 times per week. For this purpose, the cells were dissociated through the addition of Trypsin-EDTA (0.05%, Gibco, Cat#: 25300-054). HuH-7 Flp-In cell line stocks and their derivatives were cultured in medium containing zeocin (100 µg/ml, InvivoGen, Cat#: ant-zn-05) or hygromycin B Gold (200 µg/ml, InvivoGen, Cat#: ant-hg-1) depending on expressed marker genes. The parental hepatocellular carcinoma HuH-7 Flp-IN cell line (one FRT integration site; Clone C2111) was first established in (Beckmann et al. 2015), the HuH-7 p62 KO cell line in (Horos et al. 2019).

Cloning. Restriction-free cloning was performed according to (van den Ent and Löwe 2006).

CRISPR/Cas9 genome editing of cell lines. CRISPR/Cas9 genome editing was based on (Cong et al. 2013; Ran et al. 2013). In brief, guide RNAs targeting the vtRNA 1-1 locus (Supplementary Table 2, [19]) were predicted using the CRISPOR online tool (<http://crispor.tefor.net>; Version May 2017), the highest-scoring candidates

ordered from Sigma-Aldrich, annealed and ligated into BbsI linearised pSpCas9(BB)-2A-GFP/RFP/Cer constructs (Kindly provided by the Noh Laboratory, EMBL Heidelberg). Combinations of the generated plasmids were nucleofected into HuH-7 Flp-IN cells using the SF Cell Line 4D-Nucleofector X Kit according to the manufacturer's guidelines, with 1Mio cells and 1µg of total plasmid DNA in a 100 µl setup running programme FF137. As a negative control, a mixture of all parental plasmids was used. Fluorescence-activated single-cell sort of double/triple-positive cells was performed 48h after nucleofection. Upon expansion, the clones were tested for vault RNA 1-1 deletion by PCR from genomic DNA using locus spanning primers (Supplementary Table 2). Cell lines lost the transiently transfected plasmids after outgrowth as checked via FACS.

Transfections and Treatments. Transfections were performed using Lipofectamine 3000 according to the manufacturer's guidelines. For cell-based assays, XIE62-1004-A (50mM in DMSO; [19]), was diluted in PBS to a concentration of 2.5 mM and added to the medium in a final concentration of 10 µM.

Native immunoprecipitation (IP). For IPs one confluent Ø 15cm dish per IP served as starting material. The cells were washed twice with ice-cold PBS. The buffer was aspirated completely and the cells lysed on ice through the addition of 750 µl Trit-Lysis buffer (20 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 % Triton X-100) supplemented with cOmplete protease inhibitor tablets (Roche, Cat#: 11873580001) and 5 µg/ml RNAsin (Promega, Cat#: N2511). The cells were collected through scraping and homogenised by pipetting. Lysates were cleared by centrifugation for 10 min at 13 000xg, 4°C. The supernatant was transferred into a DNA LoBind 1.5 ml reaction tube (Eppendorf), the protein concentration determined

by Bradford assay and the input material adjusted accordingly (1-2 mg/IP). Per IP, 25µl anti-HA magnetic bead slurry was washed twice with PBS prior to addition to the samples. The IPs were performed for 1-2 h at 4°C with constant rotation. Following, the samples were washed six times with 1ml of Trit-Lysis buffer and the reaction tubes exchanged after every second wash. For pH elution 50µl of 0.1M glycine pH2 were added per condition and incubated for 5min at room temperature. The eluates were transferred into a new reaction tube and neutralised through addition of 7.5 µl of 1 M Tris-HCl pH8.5.

For protein analysis, 1% of input material and 15-20% of elution were analysed by Western blotting. For RNA analysis 5% of input material and 70% of elution were processed by the addition of 400 µl RNA lysis buffer (Zymo) and RNA extraction using the Zymo Quick-RNA™ MicroPrep RNA extraction kit (Zymo) following the manufacturer's guidelines including the DNaseI on-column DNA digest. Elution was performed with 15 µl RNase-free H₂O.

Polynucleotide kinase (PNK) assay of FLAG-HA tagged proteins. For the PNKs one 80-90% confluent Ø10cm or Ø15cm dish per condition served as starting material. The cells were washed twice with ice-cold PBS, the PBS was aspirated completely and the cells were UV-crosslinked at 150 mJ/cm². Subsequently, the cells were lysed on ice with 0.75-1ml PNK lysis buffer (50 mM Tris-HCl pH7.4, 100 mM NaCl, 0.1 % SDS, 1 mM MgCl₂, 0.1 mM CaCl₂, 1 % NP40, 0.5 % sodium deoxycholate supplemented with cOmplete protease inhibitors) and transferred into 1.5ml reaction tubes. The lysates were homogenized by sonication on ice (Branson cell disruptor B15: 3x 10 s, 50% amplitude, level 4) and cleared by centrifuged at 16 000xg for 10 min, 4°C. The protein concentration was measured by Bradford assay and the input material adjusted accordingly (1-2 mg/condition). Following the lysates were treated

with 5 ng/μl RNase A and 2 U/ml Turbo DNase for 15 min at 37°C and 1100 rpm. Per condition, 25 μl anti-HA magnetic bead slurry was washed twice with PBS prior to addition to the samples. The IPs incubated for 1.5-2 h at 4°C under constant rotation. Subsequently, the IPs were washed three times with PNK lysis buffer and three times with PNK wash buffer (50 mM Tris-HCl pH7.4, 50 mM NaCl, 10 mM MgCl₂, 0.5 % NP-40, supplemented with cOmplete protease inhibitors). Radioactive labelling of retained RNA was performed on beads in PNK wash buffer containing 0.1 μCi/μl [γ -³²P] ATP, 1 U/μl T4 PNK and 1 mM DTT for 15 min at 37°C and 850 rpm. After another four washes with PNK wash buffer, the proteins were eluted by addition of 50 μl 0.1 M glycine pH2 for 5 min and eluates neutralized with 7.5 μl 1M Tris-HCl pH8.5. The samples were complemented with 4x sample buffer containing 200 mM DTT, heated to 70°C for 3 min, resolved by SDS-PAGE and blotted onto nitrocellulose membranes. The membranes were rinsed, dried and radioactive signal detected with a phosphorimaging screen for 3-72 h. Following, the membrane was used for Western blot analysis. Image analysis was performed with Fiji Image J 2.0.0 ((Schindelin et al. 2012), <https://imagej.net/Fiji>). The relative PNK signal was calculated and normalised to the relative Western blot signal to account for variation in IP efficiency.

SDS-PAGE and Western blotting. For standard protein analysis cells were washed twice with ice-cold PBS, the buffer aspirated completely and cells lysed through the addition of RIPA lysis buffer (25 mM Tris-HCl pH7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS supplemented with cOmplete protease inhibitor and 0.1 U Benzonase/ml). Following the cells were collected by scraping and protein concentration measured by Bradford assay. The lysates were mixed with 4x NuPage LDS Sample buffer supplemented with 200 mM DTT before denaturation at 70°C for 3min. Typically 5-15 μg total protein were resolved by SDS-PAGE on 4-15% TGX

Precast gels using 1x Laemmli running buffer (25 mM Tris, 192 mM glycine, 0.1%SDS pH 8.3). The proteins were transferred onto PVDF or nitrocellulose membranes using the Trans-Blot Turbo Transfer System (Bio-Rad) and transfer efficiency assessed by Ponceau Red staining. The membranes were blocked in PBS-T 5% milk (1xPBS, 0.1% Tween 20, 5% w/v milk powder) for 1 h at room temperature. Primary antibodies were diluted in PBS-T 5% milk and added to the membrane overnight at 4°C under constant shaking. After three PBS-T (1xPBS, 0.1% Tween 20) washes, each for 5 min, the membrane was incubated with HRP-conjugated secondary antibody in PBS-T 5% milk for 1 h at room temperature. Following three PBS-T washes the western blots were developed using ECL on a BioRad ChemiDoc MP Imaging system with auto-capture function.

Northern blot. Typically, 15-20 µg of total RNA were mixed with 2x RNA gel loading dye (95% formamide; 0.025% xylene cyanol and bromophenol blue; 18 mM EDTA; 0.025% SDS), denatured for 5 min at 95°C, loaded onto a denaturing 8 % polyacrylamide gel (8% Acrylamide/Bis 19:1, 6 M Urea, 0.5x TBE) and separated for 1-2 h at 350 V in 0.5xTBE. A semi-dry blotting apparatus was used to transfer the RNA onto a Hybond N⁺ membrane with 0.8 mA/cm² for 2.5 h in 0.5xTBE. Following RNA and membrane were crosslinked by UV exposure at 150 mJ/cm².

The membrane was pre-hybridised (5xSSC, 7% SDS, 20 mM NaPi, 1x Denhardt solution, 0.1 mg/ml salmon sperm DNA) for 1 h at 50°C before the addition of a radioactively ³²P-labelled DNA antisense oligonucleotide probe for overnight incubation at 50°C (Supplementary Table 2). The DNA probe was labelled with PNK and purified over a Chroma Spin chromatography column according to the manufacturer's guidelines. Finally, the membrane was washed three times with a high stringency buffer (5x SSC, 2% SDS) and three times with a low stringency buffer (1x

SSC, 1% SDS) before visualising the radioactive signal by 4-16 h exposure to a phosphorimaging screen.

Protein expression and purification of recombinant full-length MBP-p62 and mutants thereof. Protein expression was performed according to (Tarafter et al. 2019).

Protein expression and purification of recombinant p62 (1-122, D69A/D71A/D73) for structural studies. The oligomerisation deficient p62 truncation p62(1-122, D69A/D71A/D73A) was cloned into pCoofy4 (Ref: PMID: 23410102) using restriction-free cloning (van den Ent and Löwe 2006), transformed into the Rosetta 2(DE3) strain and expressed in M9 medium with $^{15}\text{NH}_4\text{Cl}$ as the sole nitrogen source at 22°C O/N upon induction with 0.5 mM IPTG. The cells were lysed in a buffer containing 50 mM Tris pH 8, 750 mM NaCl, 10% glycerol, 20 mM imidazole and cOmplete, EDTA-free Protease Inhibitor Cocktail using a microfluidizer (M-110L, Microfluidics Inc., USA). Subsequently, the protein was purified from the cleared lysate by Nickel affinity chromatography (HisTrap, Cytiva) in the same buffer. The affinity tag was removed by 3C protease cleavage (EMBL, PepCore), dialysis and an additional passage over the HisTrap column. As a final purification step, oligomers were removed by gel filtration on a Superdex S75 10/300 in a buffer containing 20 mM MES pH 6.5, 100 mM NaCl, 0.2 mM TCEP and 0.05% NaN_3 .

Nuclear Magnetic Resonance Spectroscopy. NMR spectra were acquired on a Bruker Avance III spectrometer with a cryogenic triple-resonance probe and field strength of 18.8 T corresponding to proton Larmor frequency of 800 MHz) at 298 K. For NMR titrations protein samples at 80 μM concentration in 20 mM MES, pH 6.5,

100 mM NaCl, 0.2 mM TCEP, 0.05 % NaN₃ were titrated with full-length vault RNA 1-1 in the same buffer. At each titration step, an apodization-weighted sampled HSQC was collected (Simon and Köstler 2019). Spectra were processed using NMRPipe (Delaglio et al. 1995) and analysed using NMRFAM SPARKY (Lee et al. 2015). The yields and solubility of this construct did not enable sufficient signal-to-noise ratio for backbone assignments and subsequent mapping of chemical shift perturbations onto the structure.

In vitro transcription of RNA

For biochemical assays: pUC57-T7-vaultRNA1-1 plasmids were linearized and used for in vitro transcription of RNA using the MEGAshortscript kit (AM1354, Thermo Fisher) with ³²P- α UTP (SRP-210, Hartmann) according to the manufacturer's guidelines. RNA was gel purified and phenol-chloroform extracted, dissolved in water and its concentration measured by QuBit assay (Thermo).

For NMR: pUC57-T7-vaultRNA1-1 plasmids were linearized and used for in vitro transcription of RNA in a large-scale reaction containing 100 mM HEPES-KOH pH 7.5, 10 mM MgCl₂, 2 mM Spermidine-HCl, 40 mM DTT, 0.1mg/ml BSA, 7.5 mM each NTP, 800 units/ml RNasin, 10 units/ml IPP, 25 μ g/ml template DNA and 10 000 units/ml T7 RNA polymerase and incubated 8h at 37°C. The RNA was gel purified, extracted by electrophoresis, precipitated and its concentration measured by Nanodrop.

Electromobility shift assay (EMSA). Before the reaction, RNA was denatured 2 min at 95°C and subsequently refolded in the presence of 2.5 mM MgCl₂. The EMSA reactions contained typically 10 nM-2 mM protein, 10 nM radioactively labelled RNA (150 fmol, 3 kcpm), 150nM non-labelled bacterial tRNA, 1 mg/ml of BSA, 10 mg/ml

566 RNasin, 5 mM DTT, 0.5 mM PMSF, 2.5 mM MgCl₂, 100 mM KCl; 20 mM HEPES
567 pH7.9; 0.2 mM EDTA and 20% glycerol. In case of competitive EMSAs the binding
568 reaction was competed with non-labelled RNA at a typical range of 0.1 to 2 μM that
569 was added to the protein together with the labelled probe. Reactions were incubated
570 10 min at room temperature, loaded onto a native 5% acrylamide gel and ran overnight
571 at 70 V in 0.5xTBE. Subsequently, the gel was dried for 1 hour at 80°C and signal
572 visualized by exposure to a phosphorimaging screen.

573
574 **RNase footprinting.** *In vitro* transcribed RNA was dephosphorylated with Fast
575 alkaline phosphatase (FastAP) according to the manufacturer's guidelines and purified
576 over a Zymo Quick-RNA Miniprep column. Subsequently, the RNA was radioactively
577 labelled in a T4 PNK reaction with ³²P-γUTP (Hartmann) and purified over a Chroma
578 Spin chromatography column. Prior to RNase footprinting, the RNA was denatured for
579 10 min at 65°C and allowed to refold by ramping down 1°C/30s to room temperature.
580 Per condition 8 μl containing 20 μM 3'-end ³²P-labelled RNA (~1600 cps) and 6 μM
581 protein were assembled in Binding buffer (20 mM HEPES pH8, 100 mM KCl, 0.01%
582 NP-40, 5% Glycerol, 2.5 mM MgCl₂, 1 mM DTT supplemented with cOmplete
583 proteinase inhibitor (EDTA-free)) and incubated for 10 min at room temperature.
584 RNase A (5 ng/μl) was prediluted (1:200 000, 1:500 000) in H₂O and 2 μl dilution
585 added per reaction. The digest was incubated for 15 min at room temperature.
586 Following the RNA was extracted by Phenol-Chloroform extraction using TRI Reagent
587 and dissolved in 2x RNA Gel loading dye. For the alkaline ladder, 2 μl containing 20
588 μM 3'-end ³²P-labelled RNA (~400 cps) were mixed with 8 μl 50 mM NaHCO₃ pH 9.2,
589 incubated at 95°C for 5 min and supplemented with RNA gel loading dye. The samples
590 and ladder were loaded onto a denaturing 8% polyacrylamide gel (8% Acrylamide/Bis
591 19:1, 6M Urea, 0.5x TBE) and separated at 42 W (50-55°C) in 0.5xTBE. The gel was

fixed for 10 min in a bath of 6% acetic acid and 10% EtOH, dried on Whatman filter paper in a vacuum gel drier at 80°C for 40 min and the radioactive signal visualised by exposure to a phosphorimaging screen.

Chemical structure probing of RNA. Per compound four probing reactions were performed with one untreated control and three treated samples of varying concentrations. Therefore, 20 pmol *in vitro* transcribed RNA were diluted in 12 µl H₂O, denatured at 95°C for 2 min and directly transferred on ice. The RNA was allowed to fold for 20 min at 37°C upon addition of 12 µl 2x Folding buffer (40 mM HEPES pH8, 300 mM KCl, 0.02% NP-40, 10% glycerol, 5 mM MgCl₂). Subsequently, 12 µl protein [15 µM] in 1x Folding buffer was added to the reaction and incubated for 10 min at 37°C before splitting the reaction into 4x 8 µl each. For the modification reactions, 92 µl Mod. buffer A for DMS (20 mM HEPES pH7, 150 mM KCl, 0.01% NP-40, 5% Glycerol, 2.5 mM MgCl₂) or Mod. buffer B for CMCT (20 mM HEPES pH8, 150 mM KCl, 0.01% NP-40, 5% Glycerol, 2.5 mM MgCl₂) were added. For DMS treatments 1 µl of 16x, 4x or 2x DMS diluted in EtOH was added to the reactions, immediately mixed and incubated 15 min at 37°C. For CMCT treatments 5 µl, 10 µl or 15 µl of CMCT solution (42 mg/ml in H₂O) were added to the reactions, immediately mixed and incubated 15 min at 37°C. The reactions were stopped on ice, RNA extracted with TRI reagent according to the manufacturer's guidelines and EtOH precipitated. Modified residues were detected by primer extension reaction using a radiolabelled DNA oligonucleotide (T4 PNK reaction and purification over a Chroma Spin 10 chromatography column) complementary to the 3'-end of the RNA. For primer extension, 1 µl of 10 µM radiolabelled primer was annealed to 2 µl of extracted RNA and used in a 5 µl reaction with AMV reverse transcriptase according to the manufacturer's guidelines. For the sequencing lanes *in vitro* transcribed RNA was used in primer

extension reactions that contained respective ddNTPs. The reactions were stopped with 20 µl Stop buffer (50 mM Tris pH8.3, 0.5% SDS, 7.5 mM EDTA) and the cDNA EtOH-precipitated and separated on a denaturing 8% polyacrylamide gel (8% Acrylamide/Bis 19:1, 8M Urea, 0.5x TBE) at 42W in 0.5xTBE. Subsequently, the gel was fixed for 10 min in a bath of 6% Acetic acid and 10% EtOH, dried on Whatman filter paper in a vacuum gel drier at 80°C for 40 min and the radioactive signal visualised through exposure to a phosphorimaging screen.

Reverse transcription and quantitative PCR (RT-qPCR). Reverse transcription was performed with 500 ng of total RNA or 7 µl of purified RNA from IPs in a 10 µl reaction using the Maxima First-strand synthesis kit according to the manufacturer's guidelines. Control reactions that do not include the reverse transcriptase (-RT) were included for each sample. The obtained cDNA was diluted 1:20-1:50 in nuclease-free water and assembled in 10 µl qPCR reactions with 5 µl cDNA, 4.6 µl Fast SB SYBR Green Master Mix, 0.2 µl each primer (10 µM). Primer sequences can be found in Supplementary Table 2. The analysis was performed on an Applied Biosystems QuantStudio 6 Flex Real-Time PCR system in the default standard two-step cycling run. Relative expressions were calculated with the $\Delta\Delta CT$ method. The mean CT value was used when normalizing to multiple housekeeping genes.

QUANTIFICATION AND STATISTICAL ANALYSIS. Statistical analysis was performed with GraphPad Prism 8.3.1 (279; www.graphpad.com). Details for each experiment can be found in the corresponding figure legend. Image analysis was performed with Fiji Image J 2.0.0 ((Schindelin et al. 2012), <https://imagej.net/Fiji>). Structure representations were generated using PyMOL Molecular Graphics System 2.0.7 (<https://pymol.org>). NMR analysis was performed with NMRPipe ((Delaglio et al.

1995), <https://www.ibbr.umd.edu/nmrpipe/>) and NMRFAM SPARKY ([46],
<https://nmrfam.wisc.edu/nmrfam-sparky-distribution/>).

646

647 **ACKNOWLEDGEMENTS**

648 We thank Dmytro Dziuba for the synthesis of the XIE62-1004-A compound.

649

650 **REFERENCES**

651

652 Amort M, Nachbauer B, Tuzlak S, Kieser A, Schepers A, Villunger A, Polacek N.
 653 2015. Expression of the vault RNA protects cells from undergoing apoptosis.
 654 *Nature Communications* **6**: 7030.

655 Beckmann BM, Horos R, Fischer B, Castello A, Eichelbaum K, Alleaume A-M,
 656 Schwarzl T, Curk T, Foehr S, Huber W, et al. 2015. The RNA-binding
 657 proteomes from yeast to man harbour conserved enigmRBPs. *Nat Commun*
 658 **6**: 1–9.

659 Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H,
 660 Johansen T. 2005. p62/SQSTM1 forms protein aggregates degraded by
 661 autophagy and has a protective effect on huntingtin-induced cell death. *J Cell*
 662 *Biol* **171**: 603–614.

663 Bracher L, Ferro I, Pulido-Quetglas C, Ruepp M-D, Johnson R, Polacek N. 2020.
 664 Human vtRNA1-1 Levels Modulate Signaling Pathways and Regulate
 665 Apoptosis in Human Cancer Cells. *Biomolecules* **10**: 614.

666 Büscher M, Horos R, Hentze MW. 2020. ‘High vault-age’: non-coding RNA control of
 667 autophagy. *Open Biology* **10**: 190307.

- 668 Carroll B, Otten EG, Manni D, Stefanatos R, Menzies FM, Smith GR, Jurk D,
 669 Kenneth N, Wilkinson S, Passos JF, et al. 2018. Oxidation of SQSTM1/p62
 670 mediates the link between redox state and protein homeostasis. *Nature*
 671 *Communications* **9**: 256.
- 672 Cha-Molstad H, Lee SH, Kim JG, Sung KW, Hwang J, Shim SM, Ganipiseti S,
 673 McGuire T, Mook-Jung I, Ciechanover A, et al. 2018. Regulation of
 674 autophagic proteolysis by the N-recognin SQSTM1/p62 of the N-end rule
 675 pathway. *Autophagy* **14**: 359–361.
- 676 Cha-Molstad H, Yu JE, Feng Z, Lee SH, Kim JG, Yang P, Han B, Sung KW, Yoo YD,
 677 Hwang J, et al. 2017. p62/SQSTM1/Sequestosome-1 is an N-recognin of the
 678 N-end rule pathway which modulates autophagosome biogenesis. *Nature*
 679 *Communications* **8**: 102.
- 680 Christian F, Krause E, Houslay MD, Baillie GS. 2014. PKA phosphorylation of
 681 p62/SQSTM1 regulates PB1 domain interaction partner binding. *Biochimica et*
 682 *Biophysica Acta (BBA) - Molecular Cell Research* **1843**: 2765–2774.
- 683 Ciuffa R, Lamark T, Tarafder AK, Guesdon A, Rybina S, Hagen WJH, Johansen T,
 684 Sachse C. 2015. The Selective Autophagy Receptor p62 Forms a Flexible
 685 Filamentous Helical Scaffold. *Cell Reports* **11**: 748–758.
- 686 Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W,
 687 Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas
 688 systems. *Science* **339**: 819–823.

- 689 Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: A
690 multidimensional spectral processing system based on UNIX pipes. *J Biomol*
691 *NMR* **6**: 277–293.
- 692 Dikic I. 2017. Proteasomal and Autophagic Degradation Systems. *Annual Review of*
693 *Biochemistry* **86**: 193–224.
- 694 Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, Hansen M,
695 Moscat J, Diaz-Meco MT. 2011. p62 is a key regulator of nutrient sensing in
696 the mTORC1 pathway. *Mol Cell* **44**: 134–146.
- 697 Gebauer F, Schwarzl T, Valcárcel J, Hentze MW. 2020. RNA-binding proteins in
698 human genetic disease. *Nature Reviews Genetics* 1–14.
- 699 Greenberg JR. 1979. Ultraviolet light-induced crosslinking of mRNA to proteins.
700 *Nucleic Acids Res* **6**: 715–732.
- 701 Horos R, Büscher M, Kleinendorst R, Alleaume A-M, Tarafder AK, Schwarzl T,
702 Dziuba D, Tischer C, Zielonka EM, Adak A, et al. 2019. The Small Non-coding
703 Vault RNA1-1 Acts as a Riboregulator of Autophagy. *Cell* **176**: 1054-
704 1067.e12.
- 705 Itakura E, Mizushima N. 2011. p62 targeting to the autophagosome formation site
706 requires self-oligomerization but not LC3 binding. *J Cell Biol* **192**: 17–27.
- 707 Ito T, Matsui Y, Ago T, Ota K, Sumimoto H. 2001. Novel modular domain PB1
708 recognizes PC motif to mediate functional protein–protein interactions. *EMBO*
709 *J* **20**: 3938–3946.

- 710 Jakobi AJ, Huber ST, Mortensen SA, Schultz SW, Palara A, Kuhm T, Shrestha BK,
 711 Lamark T, Hagen WJH, Wilmanns M, et al. 2020. Structural basis of
 712 p62/SQSTM1 helical filaments and their role in cellular cargo uptake. *Nat*
 713 *Commun* **11**: 1–15.
- 714 Katsuragi Y, Ichimura Y, Komatsu M. 2015. p62/SQSTM1 functions as a signaling
 715 hub and an autophagy adaptor. *The FEBS Journal* **282**: 4672–4678.
- 716 Kedersha NL, Rome LH. 1986. Isolation and characterization of a novel
 717 ribonucleoprotein particle: large structures contain a single species of small
 718 RNA. *J Cell Biol* **103**: 699–709.
- 719 Lamark T, Perander M, Outzen H, Kristiansen K, Øvervatn A, Michaelsen E, Bjørkøy
 720 G, Johansen T. 2003. Interaction Codes within the Family of Mammalian Phox
 721 and Bem1p Domain-containing Proteins. *J Biol Chem* **278**: 34568–34581.
- 722 Lee SJ, Pfluger PT, Kim JY, Nogueiras R, Duran A, Pagès G, Pouyssegur J, Tschöp
 723 MH, Diaz-Meco MT, Moscat J. 2010. A functional role for the p62–ERK1 axis
 724 in the control of energy homeostasis and adipogenesis. *EMBO Rep* **11**: 226–
 725 232.
- 726 Lee W, Tonelli M, Markley JL. 2015. NMRFAM-SPARKY: enhanced software for
 727 biomolecular NMR spectroscopy. *Bioinformatics* **31**: 1325–1327.
- 728 Li F, Chen Y, Zhang Z, Ouyang J, Wang Y, Yan R, Huang S, Gao GF, Guo G, Chen
 729 J-L. 2015. Robust expression of vault RNAs induced by influenza A virus
 730 plays a critical role in suppression of PKR-mediated innate immunity. *Nucleic*
 731 *Acids Res* **43**: 10321–10337.

- 732 Li P, Zhou X, Xu K, Zhang QC. 2021. RASP: an atlas of transcriptome-wide RNA
733 secondary structure probing data. *Nucleic Acids Research* **49**: D183–D191.
- 734 Lim J, Lachenmayer ML, Wu S, Liu W, Kundu M, Wang R, Komatsu M, Oh YJ, Zhao
735 Y, Yue Z. 2015. Proteotoxic Stress Induces Phosphorylation of p62/SQSTM1
736 by ULK1 to Regulate Selective Autophagic Clearance of Protein Aggregates.
737 *PLOS Genetics* **11**: e1004987.
- 738 Moscat J, Karin M, Diaz-Meco MT. 2016. p62 in Cancer: Signaling Adaptor Beyond
739 Autophagy. *Cell* **167**: 606–609.
- 740 Mrázek J, Kreutmayer SB, Grässer FA, Polacek N, Hüttenhofer A. 2007. Subtractive
741 hybridization identifies novel differentially expressed ncRNA species in EBV-
742 infected human B cells. *Nucleic Acids Res* **35**: e73.
- 743 Nandy C, Mrázek J, Stoiber H, Grässer FA, Hüttenhofer A, Polacek N. 2009.
744 Epstein–Barr Virus-Induced Expression of a Novel Human Vault RNA. *Journal*
745 *of Molecular Biology* **388**: 776–784.
- 746 Nixon RA. 2013. The role of autophagy in neurodegenerative disease. *Nat Med* **19**:
747 983–997.
- 748 Pan J-A, Sun Y, Jiang Y-P, Bott AJ, Jaber N, Dou Z, Yang B, Chen J-S, Catanzaro
749 JM, Du C, et al. 2016. TRIM21 ubiquitylates SQSTM1/p62 and suppresses
750 protein sequestration to regulate redox homeostasis. *Mol Cell* **61**: 720–733.
- 751 Pankiv S, Clausen TH, Lamark T, Brech A, Bruun J-A, Outzen H, Øvervatn A,
752 Bjørkøy G, Johansen T. 2007. p62/SQSTM1 Binds Directly to Atg8/LC3 to
753 Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy. *J*
754 *Biol Chem* **282**: 24131–24145.

- 755 Pashev IG, Dimitrov SI, Angelov D. 1991. Crosslinking proteins to nucleic acids by
756 ultraviolet laser irradiation. *Trends in Biochemical Sciences* **16**: 323–326.
- 757 Poderycki MJ, Rome LH, Harrington L, Kickhoefer VA. 2005. The p80 homology
758 region of TEP1 is sufficient for its association with the telomerase and vault
759 RNAs, and the vault particle. *Nucleic Acids Res* **33**: 893–902.
- 760 Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome
761 engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**: 2281–2308.
- 762 Reuten R, Nikodemus D, Oliveira MB, Patel TR, Brachvogel B, Breloy I, Stetefeld J,
763 Koch M. 2016. Maltose-Binding Protein (MBP), a Secretion-Enhancing Tag for
764 Mammalian Protein Expression Systems. *PLOS ONE* **11**: e0152386.
- 765 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T,
766 Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. 2012. Fiji - an Open
767 Source platform for biological image analysis. *Nat Methods* **9**.
768 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855844/> (Accessed August
769 16, 2020).
- 770 Simon B, Köstler H. 2019. Improving the sensitivity of FT-NMR spectroscopy by
771 apodization weighted sampling. *J Biomol NMR* **73**: 155–165.
- 772 Stadler PF, Chen JJ-L, Hackermüller J, Hoffmann S, Horn F, Khaitovich P,
773 Kretzschmar AK, Mosig A, Prohaska SJ, Qi X, et al. 2009. Evolution of vault
774 RNAs. *Mol Biol Evol* **26**: 1975–1991.
- 775 Suchanek M, Radzikowska A, Thiele C. 2005. Photo-leucine and photo-methionine
776 allow identification of protein-protein interactions in living cells. *Nature*
777 *Methods* **2**: 261–268.

- 778 Sun D, Wu R, Zheng J, Li P, Yu L. 2018. Polyubiquitin chain-induced p62 phase
779 separation drives autophagic cargo segregation. *Cell Res* **28**: 405–415.
- 780 Sun L, Fazal FM, Li P, Broughton JP, Lee B, Tang L, Huang W, Kool ET, Chang HY,
781 Zhang QC. 2019. RNA structure maps across mammalian cellular
782 compartments. *Nat Struct Mol Biol* **26**: 322–330.
- 783 Tarafder AK, Guesdon A, Kuhm T, Sachse C. 2019. Recombinant Expression,
784 Purification, and Assembly of p62 Filaments. In *Autophagy: Methods and*
785 *Protocols* (eds. N. Ktistakis and O. Florey), *Methods in Molecular Biology*, pp.
786 3–15, Springer, New York, NY https://doi.org/10.1007/978-1-4939-8873-0_1
787 (Accessed March 3, 2020).
- 788 van den Ent F, Löwe J. 2006. RF cloning: A restriction-free method for inserting
789 target genes into plasmids. *Journal of Biochemical and Biophysical Methods*
790 **67**: 67–74.
- 791 Wurzer B, Zaffagnini G, Fracchiolla D, Turco E, Abert C, Romanov J, Martens S.
792 2015. Oligomerization of p62 allows for selection of ubiquitinated cargo and
793 isolation membrane during selective autophagy. *eLife Sciences* **4**: e08941.
- 794 Yang Y, Klionsky DJ. 2020. Autophagy and disease: unanswered questions. *Cell*
795 *Death Differ* **27**: 858–871.
- 796 Zaffagnini G, Savova A, Danieli A, Romanov J, Tremel S, Ebner M, Peterbauer T,
797 Sztacho M, Trapannone R, Tarafder AK, et al. 2018. p62 filaments capture
798 and present ubiquitinated cargos for autophagy. *EMBO J* **37**.
- 799 Zhang Y, Mun SR, Linares JF, Ahn J, Towers CG, Ji CH, Fitzwalter BE, Holden MR,
800 Mi W, Shi X, et al. 2018. ZZ-dependent regulation of p62/SQSTM1 in

801 autophagy. *Nat Commun* **9**.
802 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197226/> (Accessed October
803 28, 2018).
804

FIGURE LEGENDS

Figure 1: The PB1 domain and adjacent linker region are necessary and sufficient for p62's RNA binding capacity and specificity towards vault RNA1-1

(A) Schematic overview of full-length p62 and truncation constructs with N-terminal FLAG-HA tags. (FL: full-length p62; PB1: Phox and Bem1; ZZ: ZZ-type zinc finger; NLS: nuclear localisation signal; NES: nuclear export signal; TB: TRAF binding region; LIR: LC3 interacting region; KIR: Keap interacting region; UBA: ubiquitin associated domain).

(B) Schematic overview of T4 polynucleotide kinase labelling assay (PNK). Cells are UV-crosslinked to establish a covalent bond between proteins and RNA at zero-distance. Subsequently, lysates are treated with RNase A and used for immunoprecipitation followed by radioactive labelling of RNA with T4 polynucleotide kinase.

(C) PNK. Full-length (FL) p62 or different p62 truncations were expressed by transient transfection in HuH-7 p62 knockout cells and RNA binding capacity determined as described in B.

(D) Quantification of PNK assays as in C. Adjusted P values are indicated according to one-way ANOVA with Tukey correction for multiple comparisons. (n=4).

(E) Native immunoprecipitation of FLAG-HA-p62 full-length (FL) or truncation D from transfected HuH-7 p62 KO cells followed by quantitative RT-PCR of bound RNA. Indicated are adjusted p values from unpaired t-tests with Holm-Sidak correction for multiple comparisons (n=4). (vt1-1: vault RNA 1-1)

Figure 2: Lysine 7 and arginine 21 are hotspots for p62 riboregulation

- (A) p62 PB1 domain structure (PDB ID: 2KKC). Negatively and positively charged residues are highlighted in green and red, respectively.
- (B) Quantification of radioactive signal and oligomerisation in PNK assays of full-length FLAG-HA-p62 oligomerisation mutants expressed in HuH-7 p62 KO cells. Significant differences from WT construct were assessed by RM one-way ANOVA with Benjamini and Hochberg correction for multiple comparisons. (n.s.: not significant; n=4)
- (C) ^1H , ^{15}N -HSQC NMR spectrum of p62(1-122, D69A/D71A/D73A) recorded with (green) and without (black) equimolar amounts of *in vitro* transcribed full-length vault RNA 1-1. Most peaks show dramatic intensity loss upon RNA addition. Zoom-in highlights chemical shift perturbations for the remaining sharp peaks in the central region.
- (D) Representative PNK assay of full-length FLAG-HA-p62 RNA binding mutants expressed in HuH-7 p62 KO cells.
- (E) Quantification of radioactive signal and oligomerisation in PNK assays of full-length FLAG-HA-p62 RNA binding mutants expressed in HuH-7 p62 KO cells. Significant differences from WT construct were assessed by RM one-way ANOVA with Benjamini and Hochberg correction for multiple comparisons. (n.s.: not significant; n=4)
- (F) Quantification of representative EMSA with 10 nM radioactively labelled vault RNA 1-1, 60 μM BSA, 150 nM bacterial tRNAs and increasing amounts of recombinantly expressed and purified MBP-p62 WT, MBP-p62 K7A, MBP-p62 K21A and MBP-p62 R106A/R107A.

Figure 3: p62 interacts with a flexible loop in the central domain of vault RNA 1-1

(A) Chemical structure probing of *in vitro* transcribed vault RNA 1-1 in solution using Dimethyl sulphide (DMS) and 1-Cylcohexyl-(2-Morpholinoethyl)Carbodiimide metho-p-Toluene sulfonate (CMCT). The modified RNA is used for reverse transcription with a 5'-end labelled primer. The resulting cDNA is resolved on a denaturing urea-polyacrylamide gel. Residues with high and moderate reactivity are indicated in black and grey, respectively. Non-reactive residues are found in brackets. N.a. indicates that the reactivity is already observed for the non-treated control.

(B) RNase A footprinting assay. *In vitro* transcribed vault RNA 1-1 was radiolabelled at the 5'-end, incubated with recombinant MBP-p62 or BSA and subjected to limited RNase A digest followed by precipitation. RNase protection patterns were resolved on a denaturing urea-polyacrylamide gel. Arrows indicate RNase A protected nucleotides.

(C) Secondary structure model of vault RNA 1-1 based on chemical structure probing (circles corresponding to legend) with integration of RNase protection sites (arrows) from B and mean crosslink site values of vault RNA1-1 from p62-iCLIP analysis (dots). (The iCLIP data integrated in this figure were adapted from [19])

Figure 4: The flexible loop region is a key determinant of p62 riboregulation in
cellulo

(A) Schematic representation of the flexible loop region. Site of mutations are indicated by blue and green shading.

(B) Northern blot analysis of HuH-7 Flp-IN cell lines that were used to stably express vault RNA 1-1 and mutants thereof in a vault RNA 1-1 KO background (please see Supplementary Figure 5A). Vault RNA 1-1, 1-2 and 1-3 were detected with a vault RNA specific, mutation-independent probe.

(C) RT-qPCR. Expression of vault RNA 1-1 and mutants thereof was detected with a specific, mutation-independent primer pair. Individual p values are indicated according to one-way ANOVA with Benjamini and Hochberg correction for multiple comparisons. (n=5)

(D) Native p62 RIP followed by RT-qPCR. Vault RNA 1-1 and mutants thereof were detected with specific, mutation-independent primer pair. Individual p values are indicated according to one-way ANOVA with Benjamini and Hochberg correction for multiple comparisons. (n≥5).

(E) Western blot analysis of LC3B ratio. The cell lines were treated with 10 μ M XIE62-1004-A for 4 h to induce p62-specific autophagy. Lysates were analysed by Western blot.

(F) Quantification of LC3BII/I ratio in Western blot analysis as performed in E). Individual p values are indicated according to RM one-way ANOVA with Benjamini and Hochberg correction for multiple comparisons. Significance was assessed by paired Student's t-test. (n=4).

A **B** **C** **D** **E**

A

M1: U36G/U37A/U38G

M2: U36G/U37A/U38G / A46T/C47T

B **C** **D** **E** **F**

RNA

A PUBLICATION OF THE RNA SOCIETY

Vault RNA1-1 riboregulates the autophagic function of p62 by binding to K7/R21 that are critical for p62 oligomerisation

Magdalena Büscher, Rastislav Horos, Ina Huppertz, et al.

RNA published online February 24, 2022

Supplemental Material

<http://rnajournal.cshlp.org/content/suppl/2022/02/24/rna.079129.122.DC1>

P<P

Published online February 24, 2022 in advance of the print journal.

Accepted Manuscript

Peer-reviewed and accepted for publication but not copyedited or typeset; accepted manuscript is likely to differ from the final, published version.

Open Access

Freely available online through the *RNA* Open Access option.

Creative Commons License

This article, published in *RNA*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:
<http://rnajournal.cshlp.org/subscriptions>